Abstract
Transcription regulation is a complex but key control mechanism that underlies differential gene expression during development and in the adult organism. Like all protein coding genes, those encoding dopamine receptors are subject to this form of regulation as well. Modifications in dopamine receptors have been implicated in a number of neurobehavioral disorders, including Parkinson’s disease and schizophrenia, as well as in the complications of their long-term therapy (1–5). Based on clinical pharmacologic observations in parkinsonian and schizophrenic patients, the D2 dopamine receptor has traditionally been thought to be the main mediator of the motor and behavioral effects of dopamine (1,6). More recent molecular and neurophysiologic advances, in addition to the availability of receptor-selective pharmacologic agents, have clarified the importance of the D1 class of dopamine receptors as well (7,8). The D1A dopamine receptor is one of two dopamine receptors abundantly expressed in the striatum (9), suggesting that it has a critical role in transmitting the nigrostriatal dopaminergic signal resulting in normal motor function. In the prefrontal cortex, the D1A receptor is more abundantly expressed than the D2 receptor (10) and has been shown to modulate memory (11).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Lee, T, Seeman, P., Rajput, A., Farley, I. J., and Hornykiewicz, O. (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature (London) 273, 59–61.
Lee, T, Seeman, P., Tourtellotte, W. W., Farley, I. J., and Hornykiewicz, O. (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature(London) 274, 897–900.
Muller, P. and Seeman, P. (1978) Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology 60, 1–11.
Mouradian, M. M., Juncos, J. L., Fabbrini, G., Schlegel, J., Bartko, J. J., and Chase, T. N. (1988) Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part II. Ann. Neurol. 24, 372–378.
Mouradian, M. M., Heuser, I. J. E., Baronti, F., and Chase, T. N. (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann. Neurol. 27, 18–23.
Seeman, P., Ulpian, C., Bergeron, C., Riederer, P., Jellinger, K., Gabriel, E., et al. (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225, 728–731.
Chipkin, R. E., Iorio, L. C., Coffin, V. L., MaQuade, R. D., Berger, J. G., and Barnett, A. (1988) Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J. Pharmac. Exp. Ther. 247, 1093–1102.
Taylor, L. A., Tedford, C. E., and McQuade, R. D. (1991) The binding of SCH 39166 and SCH 23390 to 5-HT1C receptors in porcine choroid plexus. Life Sci. 49, 1505–1511.
Boyson, S. J., McGonigle, P., and Molinoff, P. B. (1986) Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6, 3177–3188.
Lidow, M. S., Goldman-Rakic, P. S., Gallager, D. W., and Rakic, P. (1991) Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 40, 657–671.
Williams, G. V. and Goldman-Rakic, P. S. (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572–575.
Minowa, M. T., Minowa, T., Monsma, F. J., Jr., Sibley, D. R., and Mouradian, M. M. (1992). Characterization of the 5′ flanking region of the human D1A dopamine receptor gene. Proc. Natl. Acad. Sci. USA 89, 3045–3049.
Minowa, M. T., Minowa, T., and Mouradian, M. M. (1993). Activator region analysis of the human D1A dopamine receptor gene. J. Biol. Chem. 268, 23,544–23,551.
Lee, S.-H., Minowa, M. T., and Mouradian, M. M. (1996) Two distinct promoters drive transcription of the human D1A dopamine receptor gene. J. Biol. Chem. 271, 25,292–25,299.
Lee, S.-H., Wang, W., Yajima, S., Jose, P. A., and Mouradian, M. M. (1997) Tissue-specific promoter usage in human D1A dopamine receptor gene in brain and kidney. DNA Cell Biol. 16, 1267–1275.
Graham, F. L. and Van Der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456–467.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Sanger, F., Nicklen, S., and Coulson, A.R. (1977) DNA sequencing with chainterminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463–5467.
Mizusawa, S., Nishimura, S., and Seela, F. (1986) Improvement of the dideoxy chain termination method of DNA sequencing by use of deoxy-7-deazaguanosine triphosphate in place of dGTP. Nucleic Acids Res. 14, 1319–1324.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Lee, SH., Maral Mouradian, M. (2001). Transcription Mechanisms for Dopamine Receptor Genes. In: Maral Mouradian, M. (eds) Parkinson's Disease. Methods in Molecular Medicine™, vol 62. Humana Press. https://doi.org/10.1385/1-59259-142-6:191
Download citation
DOI: https://doi.org/10.1385/1-59259-142-6:191
Publisher Name: Humana Press
Print ISBN: 978-0-89603-761-8
Online ISBN: 978-1-59259-142-8
eBook Packages: Springer Protocols